Our Team

Sam Widdicombe is responsible for Biofrontera Inc. corporate, KOL and commercial strategies and strategic accounts. She joined Biofrontera Inc. in July of 2023 bringing more than 25 years of sales and marketing leadership experience, of which more than a decade has been spent in the US Dermatology market. Prior to joining Biofrontera, Sam was at Allergan where she worked in both the medical and aesthetic areas, and then went on to hold leadership positions at Almirall and EPI Health. Sam began her career in Europe, working for GE’s Healthcare division across many disease state areas in both sales and marketing and eventually leading the UK Nuclear Diagnostics business unit. Sam has a BSc in Biochemistry from University of Birmingham and a Marketing Diploma from the Chartered Institute of Marketing.

Jon Lyons is Vice President of Scientific & Medical Affairs at Biofrontera, Inc., where he leads the strategic development and oversight of field medical engagement, medical information and communications, thought-leader initiatives, educational grants, and post-market evidence generation—including investigator-initiated research and real-world data programs. With more than 20 years of combined experience in scientific, medical, and clinical affairs and a foundational background in cancer research, Jon has been instrumental in building and operationalizing Biofrontera’s Medical Science department from the ground up.

Prior to joining Biofrontera, Jon held leadership positions at Incyte Corporation and Providence Medical Technology, managing teams of Medical Science Liaisons and Clinical Research Associates, respectively, to successfully launch first-to-market therapies in medical dermatology and spinal fusion. He also worked at DUSA Pharmaceuticals and Smith & Nephew Orthopedics. Over the past decade, Jon has consistently built and coached high-performing teams, driving programs that translate scientific innovation into measurable patient outcomes.

Jon earned his PhD in Cancer Research from The University of Texas MD Anderson Cancer Center and an MBA in Biomedical Management from the University of Memphis.

Wiebke Meyer-Wendt, PhD, joined the German Biofrontera Group in 2008 as scientist in preclinical research. Two years later, she was appointed as Head of Quality Management. In this role, she established the quality management system of Biofrontera during the change of Biofrontera’s business focus from research towards manufacturing and distribution in 2010. With the incorporation of a Global Quality Unit in 2019, she took over responsibility for the establishment, implementation and maintenance of all quality related functions of Biofrontera in the US and Europe. Since the transfer of all US assets related to Ameluz® and RhodoLED® from the German Biofrontera AG to Biofrontera, Inc. in 2025, she serves as Vice President Pharmaceutical Operations. She is responsible for ensuring that Biofrontera’s medicinal products and medical devices are manufactured so that they are fit for their intended use, comply with the requirements of the Marketing Authorization or Clinical Trial Authorization and do not place patients at risk due to inadequate safety, quality or efficacy.

Daniel Hakansson joined Biofrontera Inc. in 2019 and serves as its Senior Corporate Counsel. Dan is a trusted legal advisor to the company's leadership team, with responsibilities extending throughout the organization, including corporate governance, SEC and Nasdaq compliance, commercial contracting, and company-wide policy development. He is also a close collaborator with Biofrontera's quality assurance, regulatory, and human resources departments, where he provides guidance on a wide variety of compliance-related topics.

Before transitioning to in-house practice, Dan gained experience as a litigation attorney handling employment law and complex commercial matters, including a precedent-setting trade secret defense for a medical device component manufacturer. He earned his J.D. from the University of New Hampshire School of Law as a Daniel Webster Scholar and his B.A. in Political Science from the University of Massachusetts Amherst.

Erica Gates serves as the Vice President of Finance for Biofrontera Inc., where she provides strategic financial leadership for the company and its international subsidiaries. Erica originally joined Biofrontera in August 2019 as the Corporate Controller and has been instrumental in overseeing all aspects of financial reporting, accounting operations, and control strategies. In her current role, she is responsible for overseeing financial operations across the domestic and international entities, ensuring the integrity of financial reporting under US GAAP, maintaining strict compliance with SEC and SOX requirements, and leading the finance and accounting team.

Prior to joining Biofrontera Inc., Erica gained over ten years of progressive experience in both the pharmaceutical and financial services industries after beginning her career in public accounting at Caturano and Company in the audit practice. She brings significant experience in accounting policy, operations, and strategy, including extensive experience with public company reporting requirements. Most recently before Biofrontera, Erica served as the Corporate Accounting Manager at Affiliated Managers Group, Inc., where she was responsible for the management of financial accounting and treasury functions within a complex business structure while ensuring compliance with foreign and domestic regulatory requirements.

Erica received an M.S. in Accountancy and an M.B.A. from Northeastern University and has been a Certified Public Accountant since September 2009.

Andrew Weinburger joined Biofrontera Inc. in April 2022 as Director of IT and is responsible for overseeing the company's technology stack and ensuring its alignment with business objectives. Andrew brings many years of experience as an IT consultant, partnering with public and private organizations across a wide range of industries including manufacturing, service and consulting, private equity, non-profit, and healthcare. His broad consulting background provides a versatile perspective on technology strategy, infrastructure, and operations across diverse business environments.

Andrew received a B.S. in Computer Science from Eastern Michigan University as well as an M.B.A. and M.S. in Finance from Northeastern University's D'Amore-McKim School of Business.

Prof. Hermann Luebbert, PhD, serves as the Chief Executive Officer for Biofrontera, Inc. He studied biology in his native city of Cologne, where he completed a PhD in 1984.

After eight years of academic research at the University of Cologne and the California Institute of Technology (USA), he was awarded the habilitation at the ETH (Eidgenössische Technische Hochschule) Zürich. Prof. Lübbert has held the Chair of Animal Physiology at Ruhr-University Bochum since 1998. During his ten years at Sandoz and Novartis Pharma AG, Prof. Lübbert acquired experience in managing a globally active research organisation.

In 1997, he founded the German Biofrontera AG, which he headed as CEO until December 2021.

John J. Borer III, J.D. became a member of our board of directors in November 2021. Since 2012, he has been the Senior Managing Director and Co-Head of Investment Banking at The Benchmark Company, LLC. He was formerly the Chief Executive Officer and Head of Investment Banking at Rodman & Renshaw, and has held senior positions at Security Pacific Business Credit and Barclays American Business Credit. Mr. Borer has also served on the Supervisory Board of Biofrontera AG from May 2016 to December 2021. He holds a Doctor of Law degree (J.D.) from Loyola Law School in Los Angeles, California and a degree in Agricultural Economics from The University of California, Davis.

Dr. Hoffman is the founder, and, since 2015, has been the President and Chief Executive Officer, of Origami Therapeutics, Inc., in San Diego, California. Dr. Hoffman has over 20 years of experience in drug discovery and development. Dr. Hoffman has made major contributions to the launch of two first-in-class drugs and two best-in-class drugs for Cystic Fibrosis. Beth holds her Ph.D. in Biology from The Johns Hopkins University in Baltimore, Maryland.

Dr. Heikki Lanckriet joined the Board of Directors in July 2023. He was appointed to the Board upon the nomination of Biofrontera AG, a significant stockholder of the Company.

Dr. Lanckriet has over 20 years commercial & scientific experience in life sciences and has a track record of developing high growth technology businesses. Dr. Lanckriet has published scientific papers and is named inventor on a multitude of patents and has broad expertise and commercial experience in the life science area. He has a passion for science and innovation as well as strong commercial pragmatism. Dr. Lanckriet is currently the Chief Executive Officer of 4basebio PLC, Cambridge, United Kingdom, which is listed on the Alternative Investment Market (AIM) of the London Stock Exchange (LSE).

He is also a member of the Supervisory Boards of Biofrontera AG, Leverkusen, Germany, and Epigenomics AG, Berlin, Germany and a member of comparable domestic and foreign control committees of the following commercial enterprises: 4basebio UK Ltd and 4basebio Discovery Limited, both Cambridge, United Kingdom; 4basebio SLU, Madrid, Spain; I2I Capital Limited, Cambridge, United Kingdom; KITHER BIOTECH S.R.L., Turin, Italy; and NeoPhore Ltd, Cambridge. 

He holds a Bachelor’s and Master’s degree in Biochemical Engineering from the University of Ghent, Belgium and a PhD in Biochemical Engineering from the University of Cambridge, UK., United Kingdom.

Mr. Weber has been a member of our board of directors since 2022. He is a Principal at Skysis, LLC, a firm that provides commercial strategy consulting services to pharmaceutical, biotech and medical device companies. Prior to Skysis, LLC, he served as Chief Executive Officer of Paraffin International Inc. Prior to Paraffin, Mr. Weber served in senior executive and marketing roles at Depomed, Hyperion Therapeutics and Medicis Pharmaceuticals. Mr. Weber is also a board member of the American Chronic Pain Association and holds a B.S. in Management and Marketing from Western Michigan University.